Retinopathy of prematurity (ROP) is a leading cause of childhood blindness worldwide. It is becoming more common as emerging countries develop technology to save preterm infants, but lack resources to provide optimal care. In the United States, 14 percent of childhood blindness is attributed to ROP, while in some developing nations estimates surpass 20 percent. Treatments of severe ROP include 1) laser ablation of peripheral avascular retina, which destroys developing retina; or 2) intravitreal anti-VEGF agents, which can lead to persistent avascular retina and even blindness.

The University of Utah is developing a gene therapy based novel approach by targeting STAT3 that, unlike anti-VEGF treatment, will not interfere with physiologic retinal vascular development. This approach would stop the growth of abnormal blood vessels in the eye, prevent retinal detachment, and preserve vision.


**FEATURES AND BENEFITS**

- Novel gene therapy approach involving new pathways that overcome the limitations of anti-VEGF treatment.
- Saves time and money for patients, doctors, and insurance providers by reducing need for further eye surgery.
- Targets intravitreal angiogenesis whether VEGF caused or independently activated, which helps prevent macular degeneration and other forms of retinopathy.

**IP PROTECTION**

- Nationalized PCT Issued in the United States and Pending in Europe
- Methods and compositions for inhibiting retinopathy of prematurity
- WO2015123561A2

**LEARN MORE**

- Reference Number: U-5618

**INVENTOR PROFILE**

Mary Elizabeth Hartnett, M.D., Professor - Ophthalmology & Visual Sciences